Ariel Grajales-Cruz

9PUBLICATIONS
99CO-AUTHORS
Predictive and prognostic markersGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Regenerative medicine (incl. stem cells)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 11, 2026
Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma.

|Aug 08, 2025
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Beatrice M Razzo, Shonali Midha, Andrew J Portuguese

|Aug 01, 2025
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.

Binod Dhakal, Othman S Akhtar, David Fandrei

|Jul 09, 2025
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Beatrice M Razzo, Shonali Midha, Andrew J Portuguese

|Apr 08, 2025
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment.

Danai Dima, Aimaz Afrough, Utkarsh Goel

|Dec 09, 2024
Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes.

Ciara L Freeman, Jerald Noble, Meghan Menges

Pageof 2

Frequent Collaborators

5 joint publications

Doris K Hansen

5 joint publications

Omar Castaneda Puglianini

4 joint publications

Larry D Anderson

4 joint publications

Danai Dima